SPIA
VVOS icon

Steward Partners Investment Advisory’s Vivos Therapeutics VVOS Stock Holding History

Steward Partners Investment Advisory’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8
Closed -$25 – 4400
2025
Q2 		$25 Hold
8
– – ﹤0.01% 4083
2025
Q1 		$23 Hold
8
– – ﹤0.01% 3988
2024
Q4 		$34 Hold
8
– – ﹤0.01% 3941
2024
Q3 		$21 Hold
8
– – ﹤0.01% 3713
2024
Q2 		$18 Hold
8
– – ﹤0.01% 3595
2024
Q1 		$39 Hold
8
– – ﹤0.01% 3532
2023
Q4 		$100 Hold
8
– – ﹤0.01% 3440
2023
Q3 		$38 Hold
8
– – ﹤0.01% 3344
2023
Q2 		$102 Buy
+8
New +$78 ﹤0.01% 3268

Other funds holding VVOS

CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Steward Partners Investment Advisory's VVOS Position: Q3 2025 in Review

Steward Partners Investment Advisory sold out of Vivos Therapeutics (VVOS) in Q3 2025, closing a stake of 8 shares — an estimated $25 sold.

Steward Partners Investment Advisory first reported a position in VVOS in Q2 2023 and held it in 9 quarters. The position peaked at $102 in Q2 2023. 23 funds tracked by Wall St. Rank hold VVOS as of Q3 2025.

  • Steward Partners Investment Advisory reported no remaining Vivos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 8 Vivos Therapeutics shares in Q3 2025, an estimated $25.
  • Steward Partners Investment Advisory first reported a position in Vivos Therapeutics in Q2 2023 and held it in 9 quarters.
  • Steward Partners Investment Advisory's Vivos Therapeutics position peaked at $102 in Q2 2023.
  • 23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2025.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2025, filed 12 Nov 2025.